More Accurate, Perhaps Cheaper, Clinical Data
In the post-Vioxx era of increased scrutiny into clinical data, spiralling trial costs and a growing mistrust of drug firms' motives, the advantages of electronic diaries for use in clinical trials begin to look clearer. Their adoption has mirrored the industry's uptake of electronic data capture (EDC) systems more broadly: painfully slow until recently, but finally taking off.
You may also be interested in...
Drug firms need to conduct more, bigger, and better-monitored trials. They also need to cut costs. Electronic data capture presents a possible, but far from straightforward, solution.
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
As draft guidance receives OMB review, FDA’s determination of no economic significance reflects its official position that the thousands of supplements, food and personal care products containing CBDs available in the US are unlawful.